Memorial Sloan Kettering Cancer Center | Strategic Alliance Partners

November 05, 2025

Rohit Thummalapalli, MD, discusses the treatment paradigm for patients with GEP-NETs and the role of Lutetium Lu 177 dotatate across lines of therapy.

October 31, 2025

Komal Jhaveri, MD, FACP, discusses ocular toxicities that can be seen with the use of ADCs when treating patients with breast cancer.

October 31, 2025

Komal Jhaveri, MD, FACP, discusses management strategies for ocular toxicities and other ADC-related adverse effects in breast cancer.

October 31, 2025

Here is your guide to all therapeutic options that were approved by the FDA in October 2025 spanning tumor types.

October 21, 2025

David H. Aggen, MD, PhD, Petros Grivas, MD, PhD, and Neal Shore, MD, FACS, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in bladder cancer presented during the 2025 ESMO Congress.

September 18, 2025

Dr Drilon discusses the efficacy data and implications of the ARROS-1 trial, highlighted the mechanism of action of zidesamtinib in ROS1-positive NSCLC.

September 11, 2025

Experts preview abstracts being presented at IMS, highlighting the role of MRD, bispecific antibodies, and other strategies to refine myeloma management.

September 07, 2025

The brain-penetrant, TRK-sparing, ROS1-selective TKI zidesamtinib was active and safe in patients with advanced ROS1+ non–small cell lung cancer.

August 17, 2025

The top 5 OncLive videos of the week cover insights in MCL, prostate cancer, plexiform neurofibromas, breast cancer, and follicular lymphoma.

August 13, 2025

Dana E. Rathkopf, MD, discusses the clinical significance of findings from the phase 3 AMPLITUDE trial in HRR gene–mutated mCSPC.

July 16, 2025

Oncology experts share topline insights from 19 of the most exciting abstracts from the 2025 ASCO Annual Meeting.

July 09, 2025

Bijal Shah, MD, MS, and Jae Park, MD, discuss quality-of-life data for obe-cel in acute lymphoblastic leukemia.

July 09, 2025

Bijal Shah, MD, MS, and Jae Park, MD, discuss other key data in acute lymphoblastic leukemia from EHA 2025.

July 06, 2025

The top 5 OncLive videos of the week cover insights in myelofibrosis, AL amyloidosis, pancreatic cancer, and PIK3CA-mutated breast cancer.

July 02, 2025

Bijal Shah, MD, MS, and Jae Park, MD, discuss how inotuzumab exposure may influence response to obe-cel in ALL.

July 02, 2025

Bijal Shah, MD, MS, and Jae Park, MD, predictors of sustained remission with obe-cel in acute lymphoblastic leukemia.

June 24, 2025

Bijal Shah, MD, MS, and Jae Park, MD, discuss an age-based analysis of outcomes with obe-cel in acute lymphoblastic leukemia.

June 24, 2025

Bijal Shah, MD, MS, and Jae Park, MD, discuss how the integration of obe-cel has affected the acute lymphoblastic treatment paradigm.

June 24, 2025

Yelena Y. Janjigian, MD, discussed results from the MATTERHORN study of durvalumab plus FLOT in resectable gastric/gastroesophageal junction cancer.

June 18, 2025

Kate Gasparini, PharmD, BCOP, BCPPS, discusses issues with administering oral agents in pediatric patients with cancer or patients with dysphagia.